Annual FCF
-$72.98 M
+$11.25 M+13.36%
31 December 2023
Summary:
CymaBay Therapeutics annual free cash flow is currently -$72.98 million, with the most recent change of +$11.25 million (+13.36%) on 31 December 2023. During the last 3 years, it has fallen by -$3.46 million (-4.97%).CBAY Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$27.56 M
-$1.42 M-5.41%
31 December 2023
Summary:
CymaBay Therapeutics quarterly free cash flow is currently -$27.56 million, with the most recent change of -$1.42 million (-5.41%) on 31 December 2023.CBAY Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$72.98 M
-$8.79 M-13.70%
31 December 2023
Summary:
CymaBay Therapeutics TTM free cash flow is currently -$72.98 million, with the most recent change of -$8.79 million (-13.70%) on 31 December 2023.CBAY TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CBAY Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -5.0% | -93.5% | -5.0% |
| 5 y5 years | +25.7% | +2.1% | +25.7% |
CBAY Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | +762.8% | -541.9% | +3280.1% |
CymaBay Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$72.98 M(-13.4%) | -$27.56 M(+5.4%) | -$72.98 M(+13.7%) |
| Sept 2023 | - | -$26.14 M(+2.5%) | -$64.19 M(+15.5%) |
| June 2023 | - | -$25.51 M(-509.0%) | -$55.57 M(+5.6%) |
| Mar 2023 | - | $6.24 M(-133.2%) | -$52.63 M(-37.5%) |
| Dec 2022 | -$84.23 M(+21.2%) | -$18.77 M(+7.0%) | -$84.23 M(+5.7%) |
| Sept 2022 | - | -$17.53 M(-22.3%) | -$79.70 M(+2.7%) |
| June 2022 | - | -$22.56 M(-11.0%) | -$77.58 M(+4.5%) |
| Mar 2022 | - | -$25.36 M(+78.1%) | -$74.22 M(+6.8%) |
| Dec 2021 | -$69.52 M(+55.4%) | -$14.24 M(-7.6%) | -$69.52 M(-0.8%) |
| Sept 2021 | - | -$15.41 M(-19.8%) | -$70.09 M(+12.8%) |
| June 2021 | - | -$19.21 M(-7.0%) | -$62.15 M(+22.6%) |
| Mar 2021 | - | -$20.66 M(+39.4%) | -$50.69 M(+13.3%) |
| Dec 2020 | -$44.75 M(-54.4%) | -$14.82 M(+98.3%) | -$44.75 M(-23.0%) |
| Sept 2020 | - | -$7.47 M(-3.6%) | -$58.09 M(-21.2%) |
| June 2020 | - | -$7.75 M(-47.3%) | -$73.77 M(-18.4%) |
| Mar 2020 | - | -$14.71 M(-47.8%) | -$90.36 M(-8.0%) |
| Dec 2019 | -$98.23 M(+77.1%) | -$28.16 M(+21.7%) | -$98.23 M(+9.0%) |
| Sept 2019 | - | -$23.15 M(-4.9%) | -$90.13 M(+8.5%) |
| June 2019 | - | -$24.34 M(+7.9%) | -$83.07 M(+16.1%) |
| Mar 2019 | - | -$22.57 M(+12.5%) | -$71.55 M(+29.0%) |
| Dec 2018 | -$55.47 M | -$20.06 M(+24.7%) | -$55.47 M(+33.7%) |
| Sept 2018 | - | -$16.09 M(+25.5%) | -$41.47 M(+34.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2018 | - | -$12.82 M(+97.7%) | -$30.85 M(+29.0%) |
| Mar 2018 | - | -$6.49 M(+6.8%) | -$23.92 M(+21.8%) |
| Dec 2017 | -$19.66 M(-16.0%) | -$6.07 M(+11.1%) | -$19.63 M(+3.5%) |
| Sept 2017 | - | -$5.47 M(-7.2%) | -$18.96 M(-1.5%) |
| June 2017 | - | -$5.89 M(+167.4%) | -$19.24 M(-1.1%) |
| Mar 2017 | - | -$2.20 M(-59.2%) | -$19.46 M(-16.8%) |
| Dec 2016 | -$23.39 M(+0.3%) | -$5.40 M(-6.0%) | -$23.39 M(+0.9%) |
| Sept 2016 | - | -$5.75 M(-5.9%) | -$23.19 M(-3.8%) |
| June 2016 | - | -$6.11 M(-0.5%) | -$24.10 M(+3.4%) |
| Mar 2016 | - | -$6.14 M(+18.2%) | -$23.30 M(-0.1%) |
| Dec 2015 | -$23.32 M(+9.9%) | -$5.20 M(-22.0%) | -$23.32 M(-8.9%) |
| Sept 2015 | - | -$6.66 M(+25.4%) | -$25.60 M(+12.1%) |
| June 2015 | - | -$5.31 M(-13.8%) | -$22.84 M(+2.3%) |
| Mar 2015 | - | -$6.16 M(-17.6%) | -$22.33 M(+5.3%) |
| Dec 2014 | -$21.22 M(+150.9%) | -$7.47 M(+91.5%) | -$21.22 M(+22.8%) |
| Sept 2014 | - | -$3.90 M(-18.7%) | -$17.28 M(+23.6%) |
| June 2014 | - | -$4.80 M(-4.8%) | -$13.98 M(+23.3%) |
| Mar 2014 | - | -$5.04 M(+42.6%) | -$11.34 M(+34.1%) |
| Dec 2013 | -$8.46 M(-25.1%) | -$3.54 M(+488.5%) | -$8.46 M(+71.9%) |
| Sept 2013 | - | -$601.00 K(-72.2%) | -$4.92 M(+13.9%) |
| June 2013 | - | -$2.16 M(+0.1%) | -$4.32 M(+100.1%) |
| Mar 2013 | - | -$2.16 M | -$2.16 M |
| Dec 2012 | -$11.29 M | - | - |
FAQ
- What is CymaBay Therapeutics annual free cash flow?
- What is the all time high annual FCF for CymaBay Therapeutics?
- What is CymaBay Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for CymaBay Therapeutics?
- What is CymaBay Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for CymaBay Therapeutics?
What is CymaBay Therapeutics annual free cash flow?
The current annual FCF of CBAY is -$72.98 M
What is the all time high annual FCF for CymaBay Therapeutics?
CymaBay Therapeutics all-time high annual free cash flow is -$8.46 M
What is CymaBay Therapeutics quarterly free cash flow?
The current quarterly FCF of CBAY is -$27.56 M
What is the all time high quarterly FCF for CymaBay Therapeutics?
CymaBay Therapeutics all-time high quarterly free cash flow is $6.24 M
What is CymaBay Therapeutics TTM free cash flow?
The current TTM FCF of CBAY is -$72.98 M
What is the all time high TTM FCF for CymaBay Therapeutics?
CymaBay Therapeutics all-time high TTM free cash flow is -$2.16 M